Massive cohort requirements drive up costs and timelines
Home Industries Pharma & Biotech
For Pharma & Biotech
Smaller cohorts. Stronger biomarker signals.
Detect gene–trait associations on cohorts 10× to 100× smaller than what GWAS requires — without giving up interpretability or regulatory traceability.
Industry context
Pharma & Biotech, today.
Drug discovery and biomarker research depend on large-scale genomic studies. Rising patient recruitment costs, increasing regulatory scrutiny, and high late-stage failure rates put pressure on R&D teams to extract better insights earlier.
Key challenges
Three things hold the field back.
GWAS identifies single associations but misses complex multi-gene signals
Black-box AI tools raise regulatory and interpretability concerns
How EpiKern fits
A method built for your constraints.
Our framework detects gene–trait associations that standard methods miss — on cohorts 10 to 100× smaller. Results are fully interpretable, with no distributional assumptions. Already validated on real-world biological datasets and deployed with an industry partner.
Relevant solutions
Where to start.
Talk to us about your Pharma projects.
Tell us about your dataset, cohort size, or current bottleneck. We'll review and respond within a few working days.